{"hands_on_practices": [{"introduction": "The primary goal of maintenance therapy in schizophrenia is to prevent relapse. To make informed decisions, clinicians must be able to interpret and apply evidence from clinical trials. This practice problem [@problem_id:4724311] challenges you to derive the Number Needed to Treat ($NNT$), a fundamental metric that quantifies the absolute benefit of an intervention, using data from a typical discontinuation study.", "problem": "A multisite randomized discontinuation study evaluates maintenance antipsychotic therapy for adults with schizophrenia who have achieved symptomatic stability after an acute episode. Participants are randomized either to continue their antipsychotic regimen or to discontinue medication, and are followed for one year to observe relapse, defined using pre-specified clinical thresholds. Assume the following:\n\n- The relapse risk under continuation is $0.25$ over one year.\n- The relapse risk under discontinuation is $0.55$ over one year.\n- Outcomes across individuals are independent, and each individualâ€™s relapse probability equals the arm-specific risk.\n- The expected number of relapses in a cohort of size $n$ in a given arm equals $n$ times the arm-specific risk, by the linearity of expectation.\n\nUsing only these foundational definitions from probability and epidemiology, derive the cohort size $n$ such that the expected number of relapses prevented by continuation compared with discontinuation equals exactly one over the one-year horizon. Interpret this cohort size as the Number Needed to Treat (NNT) to prevent one relapse over one year. Express the final answer as an exact fraction with no rounding.", "solution": "The problem asks for the derivation of a cohort size, $n$, such that the expected number of relapses prevented by a maintenance treatment compared to discontinuation is exactly one. This quantity is equivalent to the Number Needed to Treat (NNT).\n\nFirst, let us formalize the given information using mathematical notation. Let $R_C$ be the relapse risk in the continuation (treatment) arm and $R_D$ be the relapse risk in the discontinuation (control) arm. The problem provides the following values for the one-year study period:\n-   $R_C = 0.25$\n-   $R_D = 0.55$\n\nThe problem states that for a cohort of size $n$ in a given arm, the expected number of relapses is the product of $n$ and the arm-specific risk. This is a direct application of the linearity of expectation for a sum of Bernoulli random variables.\n\nLet $E_C$ be the expected number of relapses in a cohort of size $n$ in the continuation arm.\n$$E_C = n \\times R_C$$\n\nLet $E_D$ be the expected number of relapses in a cohort of size $n$ in the discontinuation arm.\n$$E_D = n \\times R_D$$\n\nThe \"expected number of relapses prevented by continuation compared with discontinuation\" is the difference between the expected number of relapses in the higher-risk (discontinuation) arm and the lower-risk (continuation) arm. Let this quantity be denoted by $\\Delta E_{prevented}$.\n$$\\Delta E_{prevented} = E_D - E_C$$\n\nThe problem requires us to find the cohort size $n$ for which this number of prevented relapses is exactly one.\n$$\\Delta E_{prevented} = 1$$\n\nSubstituting the expressions for $E_D$ and $E_C$ into this equation, we get:\n$$n \\times R_D - n \\times R_C = 1$$\n\nWe can factor out the common term $n$:\n$$n (R_D - R_C) = 1$$\n\nThe term $(R_D - R_C)$ represents the Absolute Risk Reduction (ARR) achieved by the continuation therapy. Solving for $n$ gives the formula for the Number Needed to Treat (NNT):\n$$n = \\frac{1}{R_D - R_C}$$\n\nNow, we substitute the given numerical values for the risks:\n$$n = \\frac{1}{0.55 - 0.25}$$\n\nPerforming the subtraction in the denominator:\n$$n = \\frac{1}{0.30}$$\n\nTo express this as an exact fraction, we first write the decimal in the denominator as a fraction:\n$$0.30 = \\frac{30}{100} = \\frac{3}{10}$$\n\nSubstituting this back into the equation for $n$:\n$$n = \\frac{1}{\\frac{3}{10}}$$\n\nTaking the reciprocal of the fraction gives the final result:\n$$n = \\frac{10}{3}$$\n\nThis value represents the Number Needed to Treat (NNT) to prevent one relapse over one year. It means that, on average, for every group of $\\frac{10}{3}$ individuals who receive the continuation therapy instead of discontinuing it, one case of relapse is prevented.", "answer": "$$\\boxed{\\frac{10}{3}}$$", "id": "4724311"}, {"introduction": "Effective treatment involves a careful balance between therapeutic gains and potential harms. This exercise [@problem_id:4724422] extends the concept of quantifying treatment effects by introducing the Number Needed to Harm ($NNH$) alongside the $NNT$. By calculating both metrics from a single hypothetical trial, you will practice the essential clinical skill of weighing the prevention of relapse against the risk of inducing adverse effects like metabolic syndrome.", "problem": "A cohort of individuals with schizophrenia stabilized on a second-generation antipsychotic completes acute treatment and enters a randomized, double-blind, placebo-controlled maintenance phase for $12$ months. In the continuation arm, patients remain on their antipsychotic; in the placebo arm, patients receive blinded placebo. The trial reports the following $12$-month outcomes: relapse occurred in $20\\%$ of the continuation arm versus $50\\%$ of the placebo arm; incident metabolic syndrome occurred in $10\\%$ of the continuation arm versus $5\\%$ of the placebo arm. Assume equal follow-up time and negligible loss to follow-up, and that randomization ensures exchangeability so that arm-specific event proportions estimate the counterfactual risks.\n\nUsing the epidemiological framework in which the effect of treatment is quantified by differences in event probabilities between arms over a fixed time horizon, derive the Number Needed to Treat (NNT) to prevent one relapse and the Number Needed to Harm (NNH) to cause one additional case of metabolic syndrome from first principles. Treat relapse prevention as a beneficial outcome of continuation, and metabolic syndrome as an adverse outcome attributable to continuation. Express your final values as exact simplified fractions where applicable. Report the final values for the two quantities in a single row matrix, ordered as $(\\text{NNT}\\ \\text{NNH})$. No rounding is required, and no units are needed in the final answer.", "solution": "The problem is valid as it is scientifically grounded in the principles of clinical trial design and epidemiology, is well-posed with all necessary information provided, and is stated objectively. We can proceed with a formal derivation of the requested quantities.\n\nThe core of this problem lies in quantifying the absolute effect of a treatment over a fixed time horizon. The metrics Number Needed to Treat (NNT) and Number Needed to Harm (NNH) are derived from the concepts of Absolute Risk Reduction (ARR) and Absolute Risk Increase (ARI), respectively. These metrics compare the probabilities of an event occurring in the treatment group versus the control (placebo) group.\n\nLet us define the following probabilities based on the provided data for the $12$-month period:\n- Let $P_{R|T}$ be the probability of relapse in the treatment (continuation) arm. The problem states this is $20\\%$, so $P_{R|T} = 0.20$.\n- Let $P_{R|P}$ be the probability of relapse in the placebo arm. The problem states this is $50\\%$, so $P_{R|P} = 0.50$.\n- Let $P_{M|T}$ be the probability of incident metabolic syndrome in the treatment (continuation) arm. The problem states this is $10\\%$, so $P_{M|T} = 0.10$.\n- Let $P_{M|P}$ be the probability of incident metabolic syndrome in the placebo arm. The problem states this is $5\\%$, so $P_{M|P} = 0.05$.\n\nThe assumption of randomization ensuring exchangeability implies that the observed event proportions are valid estimates of the counterfactual risks, meaning the difference in outcomes between the arms can be attributed to the treatment itself.\n\nFirst, we derive the Number Needed to Treat (NNT) to prevent one relapse. Relapse prevention is a beneficial outcome. The effectiveness of the treatment in preventing relapse is measured by the Absolute Risk Reduction (ARR). The ARR quantifies the absolute difference in the risk of the adverse event (relapse) between the placebo group and the treatment group.\n\nThe ARR is defined as:\n$$\n\\text{ARR} = P_{R|P} - P_{R|T}\n$$\nSubstituting the given values:\n$$\n\\text{ARR} = 0.50 - 0.20 = 0.30\n$$\nAs a fraction, this is $\\frac{3}{10}$. The ARR represents the proportion of the population that is spared the adverse outcome (relapse) as a direct result of receiving the treatment instead of the placebo. An ARR of $0.30$ means that for every $100$ patients treated with the antipsychotic for $12$ months, $30$ relapses are prevented compared to if they had received a placebo.\n\nThe Number Needed to Treat (NNT) is the reciprocal of the ARR. It represents the average number of patients who need to be treated for the specified time period to prevent one additional adverse outcome.\n$$\n\\text{NNT} = \\frac{1}{\\text{ARR}} = \\frac{1}{P_{R|P} - P_{R|T}}\n$$\nUsing our calculated ARR:\n$$\n\\text{NNT} = \\frac{1}{0.30} = \\frac{1}{\\frac{3}{10}} = \\frac{10}{3}\n$$\n\nSecond, we derive the Number Needed to Harm (NNH) to cause one additional case of metabolic syndrome. Metabolic syndrome is an adverse outcome (harm) attributable to the treatment. The excess risk of this harm due to the treatment is measured by the Absolute Risk Increase (ARI). The ARI quantifies the absolute difference in the risk of the harmful event (metabolic syndrome) between the treatment group and the placebo group.\n\nThe ARI is defined as:\n$$\n\\text{ARI} = P_{M|T} - P_{M|P}\n$$\nSubstituting the given values:\n$$\n\\text{ARI} = 0.10 - 0.05 = 0.05\n$$\nAs a fraction, this is $\\frac{5}{100} = \\frac{1}{20}$. The ARI represents the proportion of the population that experiences the adverse outcome (metabolic syndrome) as a direct result of receiving the treatment instead of the placebo. An ARI of $0.05$ means that for every $100$ patients treated, there are $5$ additional cases of metabolic syndrome compared to the placebo group over $12$ months.\n\nThe Number Needed to Harm (NNH) is the reciprocal of the ARI. It represents the average number of patients who need to be treated for the specified time period for one additional harmful outcome to occur.\n$$\n\\text{NNH} = \\frac{1}{\\text{ARI}} = \\frac{1}{P_{M|T} - P_{M|P}}\n$$\nUsing our calculated ARI:\n$$\n\\text{NNH} = \\frac{1}{0.05} = \\frac{1}{\\frac{1}{20}} = 20\n$$\nThe problem requires expressing the final values for NNT and NNH as a single row matrix, ordered as $(\\text{NNT}\\ \\text{NNH})$. The calculated values are $\\text{NNT} = \\frac{10}{3}$ and $\\text{NNH} = 20$.", "answer": "$$\n\\boxed{\\begin{pmatrix} \\frac{10}{3} & 20 \\end{pmatrix}}\n$$", "id": "4724422"}, {"introduction": "Long-acting injectable (LAI) formulations are a cornerstone of modern maintenance therapy, designed to improve adherence and ensure stable drug exposure. Transitioning a patient from oral to LAI medication requires applying pharmacokinetic principles to calculate an equivalent starting dose and manage the transition period to avoid sub-therapeutic levels. This problem [@problem_id:4724451] provides hands-on practice in a critical clinical task, using established conversion factors and the concept of drug half-life ($t_{1/2}$) to ensure therapeutic continuity.", "problem": "A patient with schizophrenia has been clinically stable for the last $8$ weeks on oral haloperidol at a daily dose of $6$ milligrams, with good adherence and no significant adverse effects. The treatment plan is to transition to haloperidol decanoate Long-Acting Injectable (LAI) while maintaining therapeutic continuity during the first injection cycle. Use the following empirically established and widely accepted clinical pharmacokinetic facts and constraints:\n\n- Haloperidol decanoate has a terminal half-life of approximately $21$ days in typical adult patients.\n- A conservative conversion multiple from stabilized oral daily dose to initial LAI decanoate dose is $10$.\n- The maximum recommended amount for the very first haloperidol decanoate injection to reduce early adverse events is $100$ milligrams (if the calculated amount exceeds this, the remainder is scheduled separately; however, in this case, the conservative multiple will not exceed the cap).\n- The injection interval for maintenance is $28$ days for the decanoate preparation.\n\nStarting from the principle that maintenance therapy seeks to match average systemic exposure between oral therapy and LAI, and that accumulation of the LAI contribution can be approximated using first-order elimination dynamics, determine:\n\n1. The appropriate haloperidol decanoate initial dose in milligrams using the conservative multiple of the stabilized oral daily dose and applying the first-injection cap.\n2. An oral haloperidol supplementation duration during the first injection cycle sufficient to cover the lag in LAI contribution, defined here as the time until the LAI contribution reaches $50$ percent of its eventual steady-state level under first-order elimination dynamics.\n\nExpress your final answer as a row matrix with two entries: the initial haloperidol decanoate dose in milligrams and the oral supplementation duration in days. Round each entry to two significant figures. Do not include units in the final boxed answer, but use milligrams for the depot dose and days for the supplementation duration in your reasoning.", "solution": "The problem has been validated as scientifically grounded, well-posed, objective, and complete. It presents a standard pharmacokinetic conversion scenario based on established clinical principles and data. All necessary parameters are provided, and the questions are specific and formalizable.\n\nThe task is to determine two quantities: the initial dose of haloperidol decanoate Long-Acting Injectable (LAI) and the duration of oral haloperidol supplementation.\n\n**1. Calculation of the Initial Haloperidol Decanoate Dose**\n\nThe problem provides a set of rules for calculating the initial dose. Let $D_{oral}$ be the stabilized daily oral dose, and let $M$ be the conversion multiple.\nThe givens are:\n- Stabilized oral haloperidol daily dose, $D_{oral} = 6 \\text{ mg}$.\n- Conservative conversion multiple, $M = 10$.\n\nThe calculated initial LAI dose, which we will denote as $D_{LAI,calc}$, is the product of the oral daily dose and the conversion multiple.\n$$D_{LAI,calc} = D_{oral} \\times M$$\nSubstituting the given values:\n$$D_{LAI,calc} = 6 \\text{ mg} \\times 10 = 60 \\text{ mg}$$\n\nThe problem also specifies a maximum recommended amount for the very first injection, which we will denote as $D_{max,1}$.\n- Maximum first injection dose, $D_{max,1} = 100 \\text{ mg}$.\n\nWe must apply this cap to our calculated dose. The actual initial dose, $D_{LAI,initial}$, is the lesser of the calculated dose and the maximum allowed dose.\n$$D_{LAI,initial} = \\min(D_{LAI,calc}, D_{max,1})$$\nIn this case, $D_{LAI,calc} = 60 \\text{ mg}$. Since $60 \\text{ mg} \\le 100 \\text{ mg}$, the calculated dose does not exceed the cap.\nTherefore, the appropriate initial dose of haloperidol decanoate is $60 \\text{ mg}$. The problem requests rounding to two significant figures. The number $60$ can be represented as $6.0 \\times 10^1$, which has two significant figures.\n\n**2. Calculation of the Oral Supplementation Duration**\n\nThe oral supplementation duration, $t_{supp}$, is defined as the time required for the LAI contribution to reach $50\\%$ of its eventual steady-state level. The accumulation of the drug from the LAI formulation is stated to follow first-order elimination dynamics.\n\nFor a drug that accumulates according to first-order kinetics, the amount of drug in the body (or its plasma concentration) at time $t$ after the start of therapy, $A(t)$, approaches its steady-state level, $A_{ss}$, according to the following equation:\n$$A(t) = A_{ss} (1 - \\exp(-k_e t))$$\nwhere $k_e$ is the first-order elimination rate constant.\n\nThe fraction of the steady-state level achieved at time $t$ is given by:\n$$f(t) = \\frac{A(t)}{A_{ss}} = 1 - \\exp(-k_e t)$$\n\nWe need to find the time $t_{supp}$ at which this fraction is $50\\%$, or $0.50$.\n$$0.50 = 1 - \\exp(-k_e t_{supp})$$\n\nSolving for $t_{supp}$:\n$$\\exp(-k_e t_{supp}) = 1 - 0.50 = 0.50$$\nTaking the natural logarithm of both sides:\n$$\\ln(\\exp(-k_e t_{supp})) = \\ln(0.50)$$\n$$-k_e t_{supp} = \\ln(0.50) = \\ln\\left(\\frac{1}{2}\\right) = -\\ln(2)$$\n$$k_e t_{supp} = \\ln(2)$$\n$$t_{supp} = \\frac{\\ln(2)}{k_e}$$\n\nThis expression is the definition of the drug's half-life, $t_{1/2}$. The relationship between the half-life and the elimination rate constant is:\n$$t_{1/2} = \\frac{\\ln(2)}{k_e}$$\nTherefore, the time required to reach $50\\%$ of steady-state is exactly one half-life of the drug.\n$$t_{supp} = t_{1/2}$$\n\nThe problem states that the terminal half-life of haloperidol decanoate is approximately $21$ days.\n- $t_{1/2} = 21 \\text{ days}$.\n\nThus, the required duration for oral supplementation is $21$ days. This value, $21$, already has two significant figures.\n\nThe final answer requires a row matrix containing the initial dose in milligrams ($60$) and the supplementation duration in days ($21$).", "answer": "$$\\boxed{\\begin{pmatrix} 60 & 21 \\end{pmatrix}}$$", "id": "4724451"}]}